Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Sanofi-Aventis S.A. ADR (SNY)

Sanofi-Aventis S.A. ADR (SNY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Sanofi announces leadership evolution in Specialty Care Business Unit

CAMBRIDGE, Mass. , Feb. 17, 2026 /PRNewswire/ -- Sanofi today announced the appointment of Manuela Buxo as Head of Specialty Care, effective March 1, 2026. Manuela will succeed Brian Foard,...

SAN : 12.37 (-1.28%)
SNY : 47.38 (+2.69%)
Flu Season's Here—This Dividend-Payer Controls the Shot Market

With flu season in full swing, drugmakers are hoping for a short-term tailwind after a lackluster 2025. Sanofi could be the winning ticket.

JNJ : 246.91 (+0.78%)
LLY : 1,023.22 (+0.26%)
ABBV : 224.35 (-1.91%)
GSK : 60.85 (-0.54%)
CSLLY : 54.0200 (+0.61%)
PFE : 26.86 (-1.86%)
SNY : 47.38 (+2.69%)
Dynavax Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Dynavax Technologies Corporation - DVAX

NEW YORK and NEW ORLEANS , Dec. 30, 2025 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC ("KSF") are investigating...

DVAX : 15.50 (unch)
SNY : 47.38 (+2.69%)
Dynavax Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Dynavax Technologies Corporation - DVAX

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Dynavax Technologies Corporation...

DVAX : 15.50 (unch)
SNY : 47.38 (+2.69%)
Dupixent® (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial Asthma

Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung function (by 4.68% to 5.32%) compared to placebo Dupixent...

SAN.FP : 79.000 (+1.65%)
REGN : 782.38 (-1.23%)
SNY : 47.38 (+2.69%)
Dupixent® (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU)

Approval based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo In the EU, there are approximately 270,000 adults and adolescents aged 12 years...

SAN.FP : 79.000 (+1.65%)
REGN : 782.38 (-1.23%)
SNY : 47.38 (+2.69%)
UPDATE - Medidata Extends Collaboration with Sanofi for the Development of New Therapies with an Improved Patient Journey

NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Medidata , a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced an extension of their...

SAN.FP : 79.000 (+1.65%)
SNY : 47.38 (+2.69%)
Sanofi Deepens Partnership with Medidata to Expedite the Development of New Therapies with an Improved Patient Journey

NEW YORK, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Medidata , a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, and Sanofi today announced an...

SAN.FP : 79.000 (+1.65%)
SNY : 47.38 (+2.69%)
Sanofi’s AlphaMedix Achieves Key Efficacy Endpoints in Phase 2 Study

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. An update...

SNY : 47.38 (+2.69%)
Sanofi (SNYNF) Gets a Buy from J.P. Morgan

In a report released today, Richard Vosser from J.P. Morgan maintained a Buy rating on Sanofi, with a price target of €105.00. The company’s shares closed yesterday at $95.03.Elevate Your Investing...

SNYNF : 93.9700 (+2.11%)
SNY : 47.38 (+2.69%)

Barchart Exclusives

Nvidia Dumped Recursion Pharmaceuticals Stock. Should You?
Nvidia sold its position in Recursion Pharmaceuticals, while others keep a measured outlook. Does this divergence signal risk or opportunity? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar